Orteronel
Orteronel (developmental code names TAK-700) is an experimental drug that was under investigation for the treatment of prostate cancer. It is an enzyme inhibitor, specifically targeting the 17,20-lyase enzyme, a critical enzyme in the production of steroid hormones.
Mechanism of Action[edit | edit source]
Orteronel works by inhibiting the enzyme 17,20-lyase, which is involved in the biosynthesis of steroidal hormones such as testosterone and estrogen. By inhibiting this enzyme, orteronel reduces the production of testosterone, which is known to fuel the growth of prostate cancer cells. This mechanism of action places orteronel in the class of drugs known as CYP17 inhibitors, which are used in the treatment of prostate cancer that has become resistant to traditional hormone therapy.
Clinical Trials[edit | edit source]
Orteronel has been evaluated in several clinical trials for its effectiveness and safety in treating patients with metastatic castration-resistant prostate cancer (mCRPC). Early phase trials showed promise, leading to larger, phase III trials to further assess its efficacy. However, despite initial optimism, development was eventually discontinued after phase III trials did not demonstrate a significant improvement in overall survival rates for patients treated with orteronel compared to standard therapies.
Adverse Effects[edit | edit source]
Like other CYP17 inhibitors, orteronel can cause a range of side effects due to its mechanism of action. Common adverse effects reported in clinical trials include fatigue, hypertension, and liver enzyme abnormalities. As with any cancer therapy, the balance between efficacy and tolerability is crucial in the management of treatment.
Current Status[edit | edit source]
As of the last update, development of orteronel for the treatment of prostate cancer has been discontinued. The decision was based on the results of phase III clinical trials, which did not meet the primary endpoint of significantly improving overall survival in patients with mCRPC. Despite this, research into CYP17 inhibitors continues, with the hope of finding more effective treatments for hormone-driven cancers.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
